PDF(Pubmed)
Abstract：
Mitral valve (MV) disease is one of the most common valvular diseases that endangers health status. A variety of catheter-based interventions have been developed to treat MV disease. The special anatomical structures of the MV complex increase the difficulty of interventional surgery, and the incidence of perioperative complications remains high. With the continuous development of cardiovascular 3-dimensional (3D) printing technology and of multidisciplinary cooperation, 3D printing for transcatheter mitral valve interventions (TMVI) has become a revolutionary technology to promote innovation and improve the success rate. Patient-specific 3D printed models have been used in measuring sizes and predicting perioperative complications before TMVI. By simulating a bench test and using multi-material printing, surgeons may learn how the device interacts with the specific anatomical structures of the MV. This review summarizes relevant cutting-edge publications in this field and illustrates the application of 3D printing in TMVI with examples. In addition, we discuss the limitations and future directions of 3D printing in TMVI.
UNASSIGNED: ClinicalTrials.gov Protocol Registration System (NCT02917980).
UNASSIGNED: ClinicalTrials.gov Protocol Registration System (NCT02917980).
摘要：
二尖瓣（MV）疾病是危害健康的最常见的瓣膜疾病之一。已经开发了多种基于导管的干预措施来治疗MV疾病。MV复合体的特殊解剖结构增加了介入手术的难度,围手术期并发症的发生率仍然很高。随着心血管3D打印技术的不断发展和多学科合作,用于经导管二尖瓣介入治疗（TMVI）的3D打印已成为一项革命性的技术，可促进创新并提高成功率。患者特定的3D打印模型已用于测量TMVI前的大小和预测围手术期并发症。通过模拟台架测试并使用多材料打印，外科医生可以学习装置如何与MV的特定解剖结构相互作用。本文总结了该领域的相关前沿出版物，并举例说明了3D打印在TMVI中的应用。此外,我们讨论了TMVI中3D打印的局限性和未来方向。
■ClinicalTrials.gov协议注册系统（NCT02917980）。
■ClinicalTrials.gov协议注册系统（NCT02917980）。
